Orphan Drug Policy Changes To Be Considered Under US FDA's FY 2019 Budget Proposal
Executive Summary
Proposed $20m funding boost for rare disease development includes review of orphan incentives, including how to potentially stimulate development in ultra-orphan diseases.
You may also be interested in...
Opioids, Old Initiatives Dominate FY 2020 US FDA Funding Increase
The agency requested a funding increase in part to implement 2018 legislation intended to combat the opioid crisis, but also to support many initiatives in last year's budget request.
Clinical Trial Reform Is A Focus For CDER's 2019 Guidance Agenda
US FDA plans new guidances on real-world data, clinical trial statistics, and patient input in coming this year.